Telix Pharmaceuticals (TLX) Price & Analysis

Compare

455 Followers

TLX Stock Chart & Stats

Day’s Range― - ―

52-Week RangeAU$13.30 - AU$31.97

Previous CloseN/A

Volume456.62K

Average Volume (3M)3.53M

Market Cap

$5.03B

Enterprise ValueAU$8.56B

Total Cash (Recent Filing)$710.35M

Total Debt (Recent Filing)$581.45M

Price to Earnings (P/E)298.2

Beta1.25

Next Earnings

Feb 19, 2026

EPS Estimate

0.22

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.01

Shares Outstanding338,437,000

10 Day Avg. Volume3,391,135

30 Day Avg. Volume3,527,862

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap1.70

Enterprise Value/Revenue10.93

Enterprise Value/Gross Profit16.79

Enterprise Value/Ebitda92.46

Forecast

1Y Price Target

$27.54

Price Target Upside85.44% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering9

Bulls Say, Bears Say

Bulls Say

Regulatory ApprovalKey catalysts include the potential approval of Zircaix in the US and confirmation of US CMS transitional pass-through status for Gozellix.

Revenue GrowthTelix reaffirmed its $770-800MM 2025 revenue guidance for Illucix+RLS, which assumes +3% H/H growth at the midpoint.

Bears Say

Loss Of Reimbursement StatusThere is likely to be some impact on Illuccix revenue by the loss of transitional pass through status (TPT) on July 1.

Operating CostsHigher-than-expected operating costs relative to consensus expectations.

Telix Pharmaceuticals News

Telix Pharmaceuticals Secures Key Reimbursement Status for Gozellix

An update from Telix Pharmaceuticals ( ($AU:TLX) ) is now available. Telix Pharmaceuticals announced that the U.S. Centers...

7d ago

Challenger Limited Ceases Substantial Holding in Telix Pharmaceuticals

Telix Pharmaceuticals ( ($AU:TLX) ) has shared an announcement. Challenger Limited has announced that it has ceased to...

18d ago

Telix Pharmaceuticals and FDA Agree on Resubmission Pathway for TLX101-CDx

The latest announcement is out from Telix Pharmaceuticals ( ($AU:TLX) ). Telix Pharmaceuticals has reached an agreement with...

21d ago

Telix Pharmaceuticals Announces Quotation of New Securities

Telix Pharmaceuticals ( ($AU:TLX) ) has issued an update. Telix Pharmaceuticals Limited has announced the quotation of 37,949...

25d ago

Telix Pharmaceuticals to Release Shares from Voluntary Escrow

An announcement from Telix Pharmaceuticals ( ($AU:TLX) ) is now available. Telix Pharmaceuticals announced the release of 41,698...

25d ago

Challenger Limited Ceases Substantial Holding in Telix Pharmaceuticals

An update from Telix Pharmaceuticals ( ($AU:TLX) ) is now available. Challenger Limited has announced that it has...

29d ago

Telix Pharmaceuticals Reports Strong Earnings Amid Challenges

Telix Pharmaceuticals Ltd. (($AU:TLX)) has held its Q2 earnings call. Read on for the main highlights of the...

29d ago

Telix Pharmaceuticals Receives FDA Response on TLX250-CDx Application

Telix Pharmaceuticals ( ($AU:TLX) ) has issued an update. Telix Pharmaceuticals announced it received a Complete Response Letter...

1M ago

Promising Growth and Revenue Potential for Telix Pharmaceuticals: Buy Rating Justified

David Bailey, an analyst from Morgan Stanley, has initiated a new Buy rating on Telix Pharmaceuticals (TLPPF). David...

1M ago

Telix Pharmaceuticals Reports Strong Revenue Growth Amid Strategic Investments

Telix Pharmaceuticals Ltd. ( ($TLPPF) ) has released its Q2 earnings. Here is a breakdown of the information...

1M ago

Telix Pharmaceuticals announces Health Canada approval of Illuccix

Telix Pharmaceuticals announces that Health Canada has approved the use of Illuccix in selecting patients for PSMA1-targeted radionuclide...

12M ago

Telix Pharmaceuticals announces first patient dosed in Phase II CA-NINE trial

Telix Pharmaceuticals announces that the first patient has been dosed in a Phase II trial exploring the clinical...

12M ago

Telix Pharmaceuticals to acquire RLS

Telix Pharmaceuticals and RLS, America’s only Joint Commission-accredited radiopharmacy network distributing PET1, SPECT2 and therapeutic radiopharmaceuticals, announced an...

1y ago

Telix announces Cardinal Health as U.S. commercial distributor for Zircaix

Telix Pharmaceuticals has selected Cardinal Health as a commercial radiopharmaceutical distributor to supply finished unit doses of its...

1y ago

CAH

TLX FAQ

What was Telix Pharmaceuticals Ltd.’s price range in the past 12 months?

Telix Pharmaceuticals Ltd. lowest share price was AU$13.30 and its highest was AU$31.97 in the past 12 months.

What is Telix Pharmaceuticals Ltd.’s market cap?

Telix Pharmaceuticals Ltd.’s market cap is $5.03B.

When is Telix Pharmaceuticals Ltd.’s upcoming earnings report date?

Telix Pharmaceuticals Ltd.’s upcoming earnings report date is Feb 19, 2026 which is in 143 days.

How were Telix Pharmaceuticals Ltd.’s earnings last quarter?

Telix Pharmaceuticals Ltd. released its earnings results on Aug 20, 2025. The company reported AU$0.015 earnings per share for the quarter, missing the consensus estimate of AU$0.281 by -AU$0.266.

Is Telix Pharmaceuticals Ltd. overvalued?

According to Wall Street analysts Telix Pharmaceuticals Ltd.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Telix Pharmaceuticals Ltd. pay dividends?

Telix Pharmaceuticals Ltd. does not currently pay dividends.

What is Telix Pharmaceuticals Ltd.’s EPS estimate?

Telix Pharmaceuticals Ltd.’s EPS estimate is 0.22.

How many shares outstanding does Telix Pharmaceuticals Ltd. have?

Telix Pharmaceuticals Ltd. has 338,437,000 shares outstanding.

What happened to Telix Pharmaceuticals Ltd.’s price movement after its last earnings report?

Telix Pharmaceuticals Ltd. reported an EPS of AU$0.015 in its last earnings report, missing expectations of AU$0.281. Following the earnings report the stock price went up 6.974%.

Which hedge fund is a major shareholder of Telix Pharmaceuticals Ltd.?

Currently, no hedge funds are holding shares in AU:TLX

Telix Pharmaceuticals Stock Smart Score

Neutral

Fundamentals

Return on Equity

3.21%

Trailing 12-Months

Asset Growth

138.86%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Telix Pharmaceuticals Ltd.

Telix Pharmaceuticals (TLX) is a biopharmaceutical company specializing in the development of diagnostic and therapeutic products using molecularly targeted radiation (MTR). The company's primary focus is on oncology, with a pipeline that includes imaging and therapeutic products for prostate, kidney, and brain cancers. Leveraging proprietary technology, Telix aims to enhance the precision of cancer diagnosis and improve treatment outcomes.

Telix Pharmaceuticals (TLX) Earnings & Revenues

Historic Earnings Reports

TLX Company Deck

TLX Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call presented a strong performance in terms of revenue growth, product expansion, and strategic acquisitions, highlighting the company's robust cash position and pipeline advancements. However, challenges such as SEC inquiries, gross margin pressure, and competitive pricing pressures were noted.View all AU:TLX earnings summaries

TLX Stock 12 Month Forecast

Average Price Target

AU$27.54

▲(85.44% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"13":"AU$13","36":"AU$36","18.75":"AU$18.75","24.5":"AU$24.5","30.25":"AU$30.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":35.07786702369075,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">AU$35.08</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":27.5382263399,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">AU$27.54</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":16.536708739739925,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">AU$16.54</span>\n  </div></div>","useHTML":true}}],"tickPositions":[13,18.75,24.5,30.25,36],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.9,16.452143617206982,18.00428723441396,19.556430851620945,21.108574468827925,22.660718086034905,24.212861703241884,25.765005320448864,27.317148937655848,28.86929255486283,30.42143617206981,31.97357978927679,33.52572340648377,{"y":35.07786702369075,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.9,15.872171256915385,16.84434251383077,17.816513770746155,18.78868502766154,19.760856284576924,20.73302754149231,21.705198798407693,22.677370055323077,23.649541312238462,24.621712569153846,25.59388382606923,26.566055082984615,{"y":27.5382263399,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.9,15.025900672287687,15.151801344575373,15.27770201686306,15.403602689150746,15.529503361438433,15.65540403372612,15.781304706013806,15.907205378301493,16.03310605058918,16.159006722876867,16.284907395164552,16.410808067452237,{"y":16.536708739739925,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":18.01,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.97,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.45,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.55,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.61,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.34,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.46,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.35,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.99,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.05,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.07,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.15,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.9,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >